A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. - Wikidata - awgldk - TriplyDB

A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression.

A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression.

http://www.wikidata.org/entity/Q36933695

about

A20 is an early responding negative regulator of Toll-like receptor 5 signalling in intestinal epithelial cells during inflammation Lentiviral vectors in gene therapy: their current status and future potential Beyond empiricism: informing vaccine development through innate immunity research Dendritic cell-based immunity and vaccination against hepatitis C virus infection Therapeutic cancer vaccines: past, present, and future Adoptive cell therapy for sarcoma Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials A20 (TNFAIP3) alleviates CVB3-induced myocarditis via inhibiting NF-κB signaling Twist-2 controls myeloid lineage development and function A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading Usp12 stabilizes the T-cell receptor complex at the cell surface during signaling RNA Interference and Cancer Therapy The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape.p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.Solving the genetic puzzle of systemic lupus erythematosus.The polymorphisms of tumor necrosis factor-induced protein 3 gene may contribute to the susceptibility of chronic primary immune thrombocytopenia in Chinese population.Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.Control of B cell development by the histone H2A deubiquitinase MYSM1.Association of TNFAIP3 polymorphism with susceptibility to systemic lupus erythematosus in a Japanese population.Mapping quantitative trait loci for T lymphocyte subpopulations in peripheral blood in swine.Inhibitory RNA molecules in immunotherapy for cancer.Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products.Microbiome and immunological interactions.Epigenetic control of dendritic cell development and fate determination of common myeloid progenitor by Mysm1.A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells.A20 controls macrophage to elicit potent cytotoxic CD4(+) T cell response.Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells Dendritic cell-based vaccines: barriers and opportunities Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity.The E3 ligase c-Cbl regulates dendritic cell activation Overexpression of the human ZNF300 gene enhances growth and metastasis of cancer cells through activating NF-kB pathway In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models.Neurodegenerative and inflammatory pathway components linked to TNF-α/TNFR1 signaling in the glaucomatous human retina.Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.In Vivo Silencing of A20 via TLR9-Mediated Targeted SiRNA Delivery Potentiates Antitumor Immune Response A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses

P2860

Q24317005-C92D6622-0739-4CF1-A55A-E4E999747EB7 Q24629462-0713AF4F-8DFB-41AE-AEBE-285C6BBEDC21 Q26824573-555290FF-2EF8-422F-AC77-5B172529F620 Q26828003-079509C5-B02A-45A3-A6C8-9F37B8D7736B Q26863283-D5AE9D72-922E-498C-A307-1F6DB8EA8A6B Q27009541-8B5711C1-C905-4AC7-A580-271A1F29AB4D Q27014829-E0E5BA00-0F7A-4D3A-A373-ABA235F14F38 Q27316099-B8BE8DCB-9093-4551-BA45-BAD7C2D5359C Q28507168-8A4D2238-F174-4203-B56F-BCA9C3245278 Q28537598-64289F2E-B007-4A59-BFF6-94E202B2590D Q28941247-E0C35596-9479-4E97-B028-B78CDF1B5815 Q29392204-B9360851-6ADE-4125-BC61-F80BEBD30A2A Q30317628-C0D1F6EE-50CC-4702-9853-187D2B05B747 Q30422500-41DC125C-9119-4728-B1EE-9FF7D01354C9 Q33359121-79652346-DB98-4672-B0A1-D65F15E06578 Q33421426-F46D6AD5-AA14-406D-A51D-A9280E914CB6 Q33689478-FD44E06E-4469-49C9-8927-1DE7978D0E14 Q33903347-4560E06A-D934-4532-AB12-82FDDD86A646 Q33959958-C47F3A3B-24DC-411D-8586-5F1E6ED0A4FF Q34020900-8B96FE34-359F-4F86-B20B-95017EDB5DF1 Q34033910-3AA461C4-F6FA-4AAA-9505-86990A2296D4 Q34077474-90BE2B99-9A17-4A20-8458-2A82C19ADECB Q34149945-C2DD5DB9-4BDA-4FE0-A764-AE7F08C0B5B9 Q34292157-416BB45F-F13C-4C69-B10E-BEC446467AB3 Q34398362-9113897C-289D-4275-9C30-5B370A35FB79 Q34473345-01B3B338-2B51-43BE-9B32-A58C55E80ECC Q34473746-7BB966DE-A84A-48C1-84CA-364952924412 Q34519838-D72CF4A8-929C-4BDC-9C9D-4588C1CC02E6 Q34661797-9FCA5484-2982-4AFE-8B2B-E5343C696480 Q34730651-122FD9F4-7DEB-4C34-95B9-A59DF576A81E Q35156105-2FD10FC0-FC31-4F89-A8C3-BD2A7A4F8D8A Q35194794-899D7C34-7B72-4D70-B124-FEEC044BF3AF Q35195028-64C0CEC1-DCAF-4AA4-A4B8-64AF6EA137A7 Q35217609-CE8F9B97-7C63-46A1-AAB6-CB8F993243B0 Q35524470-0EA79C55-1F2E-466C-9486-BBFA24ECA62C Q35543558-905E525B-4AEB-4459-903E-192201FA19F2 Q35750026-EB9D7E55-25FB-45C3-BA9A-56BA867A901D Q35761188-BE6A8D4C-814B-4CC8-B06A-E171A4C89A07 Q35857642-1AF00ACE-2AE7-4C6B-89C1-FC36C6442380 Q35990046-80D0C723-E193-41EB-862D-E3271829C621

P2860

A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression.

http://www.wikidata.org/entity/Q36933695

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

A20 is an antigen presentation ...... y T cell-mediated suppression.

@en

type

label

A20 is an antigen presentation ...... y T cell-mediated suppression.

@en

prefLabel

A20 is an antigen presentation ...... y T cell-mediated suppression.

@en

P1433

Q36933695-9B82099D-7F99-4E98-ADFD-76CEB90E8E20

P1476

Q36933695-60AE87C5-379E-4B41-9495-45AA0BD667FC

P2093

Q36933695-044DDEDA-22CA-4E3D-A729-C48BA494E176

Q36933695-272C6436-61B9-476E-B828-54E2D205DAF9

Q36933695-A8D04C2E-B3C4-4F65-93E8-79A90DDCC89C

Q36933695-AEFF1C46-B289-4A2A-A8F5-14980DE8931C

Q36933695-BE011FC8-FA60-4B88-AD95-16358ED53FE4

Q36933695-F1E68357-D55A-4C76-8507-C07C496C9292

P2860

Q36933695-01F03FE0-3E50-4DC2-89FF-F8B9D950B941

Q36933695-039A48E5-5590-4F0D-8AF1-17380723C013

Q36933695-10A5E21B-B267-4989-9D8D-463B6B72F1C6

Q36933695-11FDFE38-752D-4E97-99E4-A59D14C09558

Q36933695-16556FE9-5EBE-4209-AECA-E687D9DDA780

Q36933695-230866C6-4884-4D79-818C-1380F40A2EA6

Q36933695-440543D1-3A9E-499F-AC3E-CF18F3626701

Q36933695-4B49430A-C001-41EC-A401-193CBF35F640

Q36933695-50012C0D-81A2-482A-9B7D-4475003F138D

Q36933695-55126AE6-31C1-491B-B4E8-73EA1FBE3784

P2888

Q36933695-4125E70E-A79B-40EB-8070-3B5B444F506C

P304

Q36933695-5E8F8752-EE44-4114-B08F-2D1D343DF620

P31

Q36933695-8772FCC6-99C1-4056-BF81-094C0ECB53E6

P356

Q36933695-8C82D377-D0CD-4C42-BDF7-3B799952CE72

P407

Q36933695-D6A2DDE1-FC65-4AE6-8E4B-4DCF45A8344B

P433

Q36933695-C7EAE020-A63C-4C1B-8AAD-6B5C9AB10B78

P478

Q36933695-96558D7C-CA6B-47A2-BD8F-5E21875311C7

P577

Q36933695-0D528376-7C97-48E3-A56B-1A097337B1F6

P5875

Q36933695-E691BA20-FB48-47D9-9501-E2FC2AF3891F

P6179

Q36933695-F7F7C385-33E3-409C-AE95-275BF7592106

P698

Q36933695-29DC2C09-E1F6-4505-82F4-8A1B0EEFD458

P932

Q36933695-7563BC8A-A566-46C4-8079-6DB9B6FC7D93

P356

P1433

Nature Medicine

P1476

A20 is an antigen presentation ...... y T cell-mediated suppression.

@en

P2093

Kevin Evel-Kabler

http://www.w3.org/2001/XMLSchema#string

Lei Shen

http://www.w3.org/2001/XMLSchema#string

Lisa Rollins

http://www.w3.org/2001/XMLSchema#string

Si-Yi Chen

http://www.w3.org/2001/XMLSchema#string

Xiao-Tong Song

http://www.w3.org/2001/XMLSchema#string

Xue F Huang

http://www.w3.org/2001/XMLSchema#string

P2860

De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

Cancer immunotherapy: moving beyond current vaccines

Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice

Dendritic cells and the control of immunity

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

P2888

P304

258-265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1721

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5541502

http://www.w3.org/2001/XMLSchema#string

P6179

1049410433

http://www.w3.org/2001/XMLSchema#string

P698

18311150

http://www.w3.org/2001/XMLSchema#string

P932

3684168

http://www.w3.org/2001/XMLSchema#string